Analyzing CVRx (CVRX) and Its Competitors

CVRx (NASDAQ:CVRXGet Rating) is one of 213 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare CVRx to similar businesses based on the strength of its analyst recommendations, profitability, institutional ownership, earnings, valuation, dividends and risk.

Earnings & Valuation

This table compares CVRx and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CVRx $13.04 million -$43.08 million -0.11
CVRx Competitors $1.15 billion $84.78 million -477.04

CVRx’s competitors have higher revenue and earnings than CVRx. CVRx is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares CVRx and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CVRx -311.83% -148.64% -33.31%
CVRx Competitors -677.61% -64.37% -19.11%

Analyst Recommendations

This is a summary of current ratings and recommmendations for CVRx and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CVRx 0 0 3 0 3.00
CVRx Competitors 1264 4578 7981 221 2.51

CVRx presently has a consensus target price of $20.84, suggesting a potential upside of 294.03%. As a group, “Surgical & medical instruments” companies have a potential upside of 57.67%. Given CVRx’s stronger consensus rating and higher possible upside, analysts clearly believe CVRx is more favorable than its competitors.

Insider & Institutional Ownership

65.9% of CVRx shares are owned by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 14.3% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About CVRx (Get Rating)

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.